U.S. Markets open in 2 hrs 20 mins

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
271.25-8.56 (-3.06%)
At close: 4:00PM EDT

271.10 -0.15 (-0.06%)
Pre-Market: 6:48AM EDT

People also watch
  • I hope nobody here got squeezed out when the stock sold off so badly. I really do think an announcement is coming and those in the know have been manipulating the stock price. glta
  • Every time I sell, then it goes up , what the hell
  • .....03:12 PM EDT, 06/21/2017 (MT Newswires) -- Shares of Biogen (BIIB) climbed more than 4% and peers also advanced intraday after a draft of an executive order on drug prices showed President Trump appears to give the pharmaceutical industry much of what it has asked for -- and no guarantee that costs to consumers will drop, according to a report from New York Times.
  • High volume today. Institutional buying!
  • go sidewey fer awhile? consolidate, and then anuther surge? jus wondering
  • Hey guys it may be time to look at some beaten down oil stocks for a quick run! Every dog has its day in this man's market! lol
  • Glad I sold Biib at $421/sh....I thugh this was overbought
  • This whole bio ride has been so hilarious... in March/April, the analysts were bashing every bio in sight and saying they were all #$%$ and the index fell from like 209 to 195. They kept bashing. Then the index broke support at 195 and went down to 189 for a day before bouncing back to 195... Ok, so now the index has run from 189 to 215 in short order. Keep in mind that it takes about $45M in total gains to go up 1 point, so we've gained about 1.1B in asset value. NOW the analysts are coming out of the wood work and upgrading all the bios left and right... Uh... you guys already missed the 26 point index run. I don't mind you guys helping push it higher, but just shows how useless analysts are.
  • Still saying the shake-up in BIIB management is not coincidental, new talent is coming in. I smell something is definitely in the making!
  • Is BIIB overvalued at current levels? I started receiving notifications from AWEsome_STOCK.S the other week and so far they have presented interesting new trade ideas.
  • (AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....GLTA ! Next Biogen in the making here ....

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • down 2 percent over a bean counter.
  • BIIB just hired a new HR head: Biogen appoints Ginger Gregory executive vice president, chief human resources officer
    * Biogen Inc ( BIIB ) - Gregory, was most recently chief human resources officer at Shire Pharmaceuticals Source text for Eikon: Further company coverage
  • Thestreet article says the sell off was an overreaction and nothing points to internal issues. Obviously we aren't going up +8 tommorow, but feels like a one day event to me.
  • It's crazy how much $ I lost out on. I sold 300 shares a couple weeks ago at 255!
  • BIIB is up 4.91% to 279.06
  • What happened after hours? BIIB dropped like its hot
  • BIIB will not have any significant move until Aducanumab picks up some exciting. This is a potential game change drug with peak sale anywhere between 5 to 20 billions. So far it looks promising. One year have has passed by since it entered into phase 3. The earlier phase results looked very exciting. The improvement on the key biomarker - clearance of amyloid deposit - is beyond any doubt. The two cognition measurements were also significant although not as remarkable as the biomarker. It is most likely due to belated effect on these two measurements.
    It looks like Biogen will have read-out data some time next year (the trial will not be finished until 2020). This will probably be the most anticipated event in drug industry
  • This pretty much seals the deal for a takeover. Question isn't if but when? All the signs are there. First CEO Scangos leaves, then they spinoff most important asset to form BIIV, then others exit, including the head of Human Resources, and now Clancy, the CFO! JUST GET ER DONE DAMMIT!!!!
  • CFO leaving to Alexion is good news for Alexion... get a good, honest management team in there. Seems pretty irrelevant to Biogen imo. Not like the company is going to fall apart without him. Just overreaction as people think other top folks will leave.